Q1 Production’s 6th Annual Pharmaceutical & Biotech Medical Affairs Pre-Launch Strategies Conference

June 14, 2021 11:50:41
Date: June 16-18, 2021 Virtual Event Event Highlights
  • The virtual event aims to promote the attainment of pre-launch excellence in strategic cross-functional alignment by optimizing publication strategies and supporting product approvals
  • The three-day event adopts a half-day format to maximize retention and engagement
  • It will feature two 15-minute networking and coffee breaks daily, complemented by a virtual platform that supports an array of networking features beyond the capabilities of a Zoom meeting
  • The event will take a broad educational approach in which 25+ facilitators will provide industry insights through case studies, presentations, Q&A sessions, and panel discussions
The 6th Annual Pharmaceutical & Biotech Medical Affairs Pre-Launch Strategies Conference, a three-day virtual event to be held June 16-18, 2021, focuses on achieving pre-launch excellence in strategic cross-functional alignment by optimizing publication strategies and supporting, at an evidentiary level, the approval of products. Organized by Q1 Production, the event will take an educational approach, comprising case studies, panel discussions, Q&A sessions, and presentations, and feature a half-day format for the three days to maximize engagement and retention. Further, it will be held on the Q1 Productions virtual event app that enhances both collaboration and networking. As a three-day event, the agenda is divided into three modules, each representing a day’s program. The event will kick off with a presentation on the Innovative approaches for enhanced HCP engagement, of course, after the opening remarks from Q1 Productions. A second presentation will follow 45 minutes later in which Brant Jarrett, PhD, Executive Director, Head of Field Medical Affairs at Mallinckrodt Pharmaceuticals (OTC: MNKKQ), will explore how to shape new pre-launch processes following the disruption caused by the COVID-19 pandemic. A 15-minute coffee and networking break will follow. Day one will continue in earnest thereafter, with a video chat featuring a panel of three facilitators, followed by three other presentations. In all, the first day will feature nine speakers drawn from various companies that deal with pharmaceuticals, biotechnology, and medical affairs. Module 2 will begin with a two-part session series titled Practical approach to investigator-initiated trial integration into the medical strategy; the second part will be a panel discussion. In total, day two will feature two panel discussions and three presentations by ten speakers holding senior positions in at companies like Taiho Oncology, Mallinckrodt Pharmaceuticals, Daiichi Sankyo (TYO: 4568), Alkermes PLC (NASDAQ: ALKS), Coherus Biosciences Inc (NASDAQ: CHRS), and more. Day three’s program will include presentations and panel discussions from seven speakers, who will explore the following topics: natural language processing, product differentiation in highly competitive markets, partnering to maximize data relevance and payer adoption, and, lastly, collaborating with the patient advocacy department to expose gaps in medical strategies. Q1 Productions, an event organizer leveraging more than 15 years’ experience to deliver educational programming across job functions and industries through curated events, understands attendees’ needs. In this regard, Q1 has facilitated the customization of attendees’ experiences and provided an opportunity for them to get answers to their unique concerns by integrating Q&A sessions into the program, particularly after every presentation or panel discussion. Furthermore, there will be two 15-minute networking and coffee breaks daily. These breaks, coupled with the features on its virtual platform that promote collaboration, are bound to make the conference an interactive and fun experience for everyone in attendance. Attendees should expect to learn about the blueprints that ensure the objectives of R&D and commercial teams remain cardinally aligned to the goals of an organization and how their peers ethically distribute scientific information about products to stakeholders. In sum, this curated conference is exquisitely loaded with a mixed bag of informative and networking sessions ideal for players in the medical affairs and medical science liaison professions. For more information regarding the event, visit https://ibn.fm/EuzVq

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office www.InvestorWire.com Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.